A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight
← catalyst calendarSponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · Double · Basic science
Enrollment
30actual
Sites
1
Country
Singapore
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-04-21 | actual | When the study began enrolling |
| Primary completion | 2025-09-09 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-09-09 | actual | The whole study's end, after follow-up |
| First posted | 2025-04-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Obesity
- Overweight
Interventions
- Drug: Eloralintide — also filed as LY3841136
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFNumber of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
measured Baseline to Study Completion (Up to 10 Weeks)
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed